<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372064">
  <stage>Registered</stage>
  <submitdate>1/08/2017</submitdate>
  <approvaldate>25/08/2017</approvaldate>
  <actrnumber>ACTRN12617001240336</actrnumber>
  <trial_identification>
    <studytitle>Brain blood flow, type 2 diabetes, and high-intensity interval training.</studytitle>
    <scientifictitle>High-intensity interval training in type 2 diabetes.  Does it improve brain blood flow, cognitive function and reduce the risk of cerebrovascular disease?</scientifictitle>
    <utrn>U1111-1182-1377 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <healthcondition>Cerebrovascular Health</healthcondition>
    <healthcondition>Cognition</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will be randomised to six months of high-intensity interval training will be compared to standard clinical management. For the first two months, the participants will be supervised by an exercise physiologist during exercise three times a week after which the participants will be encouraged to complete at least one session a week on their own (not compulsory). Cycling on a stationary ergometer will be completed during the supervised session at the School of Physical Education Sports and Exercise Science, University of Otago, Dunedin. If the participants decide to complete a session on their own, they will be free to undertake an exercise modality of their choice as long as they are following the high-intensity interval protocol which is provided as an attachment.
The sessions last for 20  30 min including a short warm up and cool down. The high-intensity interval training protocol is graduated targeting a heart rate of 90% of their age-predicted max (220  age) see attached protocol which is attached to the ANZCTR registration form, interspaced lower intensity exercise which is participant self-selected. 
The participants heart rates will be recorded for each session using individualised Polar Heart Rate monitors. The Polar Heart Rate monitors are given to the participants randomised to high-intensity interval training for the duration of the study. These recordings will be used to assess adherence and compliance to the training protocol. The participants will be contacted by study personnel at least on a weekly basis in the high-intensity interval group.</interventions>
    <comparator>In those who identify as having type 2 diabetes three months of standard clinical diabetes management as prescibed by their general practitioner will be the control comparator. These participants will be encouraged to remain in contacted with study personnel. Study personnel will contact them on a fortnightly basis.  

Those participants without type 2 diabetes will not be randomised into the interventional groups. They will be compared to those with type 2 diabetes at baseline to assess the extent that diabetes affects brain blood flow, its reserve, and cognitive function.</comparator>
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Brain blood flow reserve assessed with postural change.

Brain blood flow will be measured using transcranial Doppler ultrasound insonating the middle cerebral artery. 

The brain blood flow response to changes in posture which transiently alters arterial blood pressure will be assessed during repeated sit-to-stand tests for 5 minutes, each sit or stand phase will last 10 seconds. </outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Brain blood flow reserve assessed with alterations in arterial carbon dioxide.

Brain blood flow will be measured using transcranial Doppler ultrasound insonating the middle cerebral artery. 

The brain blood flow response to changes in arterial carbon dioxide, giving an indication of chemical regulation of brain blood flow. This will be assessed i) during two stepped increases in arterial carbon dioxide of 5 mm Hg for 5 minutes, by controlled supplementation of 100% medical grade carbon dioxide into the inspired air. ii). during two stepped decreases in arterial carbon dioxide of 5 mm Hg for 5 minutes, by getting the participants to voluntarily hyperventilate (increase thier rate and depth of breathing).</outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive function assessed in the executive domain using an automated computerised Stroop test.</outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiorespiratory capacity during an aerobic capacity test using an incremental protocol on a cycle ergometer.</outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Venipuncture for glycosylated haemoglobin. </outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Venipuncture for plasma lipid profiles.</outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood volume will be measured using carbon monoxide dilution rebreathing.</outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Venipuncture for fasting glucose.</outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Venipuncture for fasting insulin.</outcome>
      <timepoint>Baseline for all participants and in those with type 2 diabetes post-intervention  Those randomised to high-intensity interval training will be reassessed at 6 months; Those randomised to standard clinical management will be reassessed at 3 months, and then will be offered to cross over to 6 months of high-intensity interval training then reassessed.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For those who identify as having type 2 diabetes.
Confirmed diagnosis of Type 2 diabetes
Aged between 40 - 65 years
Able to give informed consent

For those who identify as healthy volunteers.
Aged between 40 - 65 years
Able to give informed consent</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>For those who identify as having type 2 diabetes.
Unable to give informed consent
Any pre-existing cardiovascular and cerebrovascular disease and peripheral neuropathy
Currently treated with beta-blocker or rate control therapy

For those who identify as healthy volunteers.
Found to have undiagnosed type 2 diabetes.
Unable to give informed consent
Any pre-existing cardiovascular and cerebrovascular disease and peripheral neuropathy
Currently treated with beta-blocker or rate control therapy
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Based on estimates from Petrica, et al 2007 (Wein Klin Wochenschr 119(11-12): p 365-71) where brain blood flow reserve was reduced by 6.6 Â± 1.5 cm.s-1 in people with diabetes than those without.  We anticipate 10 participants per group to detect a difference of a one-third between the non-diabetic controls and the participants with diabetes, and improvement in brain blood flow reserve with the training of one-third (90% power, P &lt;0.05). Allowing for loss to attrition we will recruit 15 participants per diabetic group (total of 30).</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>21/06/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <currentsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>21/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>University of Otago
PO Box 56
Dunedin 9054</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Lottery Health Research</fundingname>
      <fundingaddress>The Department of Internal Affairs
147 Lambton Quay
WELLINGTON 6011
PO Box 805
WELLINGTON 6140</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Healthcare Otago Charitable Trust</fundingname>
      <fundingaddress>Private Bag 1921
Dunedin 9054</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People with type 2 diabetes require a disproportionate amount of New Zealands medical resources. These patients are twice as likely to have cardiovascular and cerebrovascular disease as non-diabetics. In fact, 65% of cardiovascular and cerebrovascular disease admissions are people with type 2 diabetes, and account for ~30% of inpatient hospitalisation cost, which is predicted to increase in the future. Therefore, prevention of diabetic cerebrovascular disease is important for directing the development of preventative strategies to mitigate the social and economic burden for New Zealand.
Stroke the most severe outcome of cerebrovascular disease causes prolonged morbidity and consumes ~$50,000 per case. We know that people with diabetes are twice as likely to suffer from a stroke, which may be caused by alterations in brain blood flow or its reserve that appears to occur in people with diabetes. These changes elevate the risk of cerebrovascular disease including stroke in other populations. In addition, there is indirect evidence that brain blood flow is perturbed with diabetes, with multiple studies showing cognitive function is more commonly impaired. Impaired cognitive function is associated with reduced and/or abnormal brain blood flow in other populations. 
Three months of exercise training in healthy but previously sedentary people improves cognitive function, brain blood flow and its reserve. However the effect of exercise on brain blood flow has not been tested in people with diabetes. The clinical high-intensity exercise programme our laboratory uses, may offer a simple tool to improve brain blood flow, cognitive function and reduce the risk of cerebrovascular disease in people suffering from type 2 diabetes. Our research group has recently used HIT to improve daily blood glucose in a small group of pre-diabetic participants. High-intensity interval training interspaces bursts of intense exercise reaching 90% of individual maximum heart rates with periods of exercise at lower intensities. Importantly, HIT improves blood glucose and fitness more than traditional exercise recommendations, and seems to be more popular.  We now propose to enrol diagnosed diabetic patients in a six month HIT program to test the hypothesis that this popular exercise method can improve brain blood flow, cognitive function and reduce cerebrovascular disease risk. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern B Health and Disability Ethics Comittee</ethicname>
      <ethicaddress>C/- Ministry of Health
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>22/09/2017</ethicapprovaldate>
      <hrec>17/NTB/145</hrec>
      <ethicsubmitdate>19/07/2017</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/372064-HIT protocol.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Luke Wilson</name>
      <address>Department of Medicine
Dunedin School of Medicine
University of Otago
PO Box 56
Dunedin 9054</address>
      <phone> +64274491401</phone>
      <fax />
      <email>luke.wilson@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Luke Wilson</name>
      <address>Department of Medicine
Dunedin School of Medicine
University of Otago
PO Box 56
Dunedin 9054</address>
      <phone> +64274491401</phone>
      <fax />
      <email>luke.wilson@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Luke Wilson</name>
      <address>Department of Medicine
Dunedin School of Medicine
University of Otago
PO Box 56
Dunedin 9054</address>
      <phone> +64274491401</phone>
      <fax />
      <email>luke.wilson@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Luke Wilson</name>
      <address>Department of Medicine
Dunedin School of Medicine
University of Otago
PO Box 56
Dunedin 9054</address>
      <phone> +64274491401</phone>
      <fax />
      <email>luke.wilson@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>